Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10961310 Targeted immunotolerance

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Date Filed
March 15, 2018
Date of Patent
March 30, 2021
Patent Application Number
15922592
Patent Citations
‌
US Patent 10350266 Method of treating cancer with a multiple integrin binding Fc fusion protein
‌
US Patent 10493148 PD-1 agonist antibodies and uses thereof
‌
US Patent 10676516 Targeted immunotolerance
‌
US Patent 10751414 Methods of treating psoriasis using PD-1 binding antibodies
‌
US Patent 10766958 Methods of treating vitiligo using PD-1 binding antibodies
‌
US Patent 10035836 Modified IL-2 variants that selectively activate regulatory T cells
‌
US Patent 10086046 Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory T cells
‌
US Patent 10093711 Interleukin-2 muteins for the expansion of T-regulatory cells
‌
US Patent 10130659 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
‌
US Patent 10137206 Nucleic acid products and methods of administration thereof
•••
Patent Citations Received
‌
US Patent 12091440 IL2 and peptide-MHC complex fusion proteins and methods of use thereof
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10961310
Patent Primary Examiner
‌
Nelson B Moseley, II

Find more entities like US Patent 10961310 Targeted immunotolerance

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo